United Pharm Total Assets
United Pharm total assets. Based on the latest financial reports, United Pharm (033270) holds total assets worth ₩570.76 Billion KRW (≈ $386.79 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see cash efficiency ratio of United Pharm for how efficiently the company converts equity into cash flow.
Total Assets of United Pharm (2011–2025)
Total assets of United Pharm from 2011 to 2025. This chart illustrates how United Pharm's total assets have evolved over time, based on quarterly financial data. See United Pharm stock price for real-time trading data and today's change.
United Pharm - Asset Composition Analysis
United Pharm Total Assets Breakdown (December 2025)
United Pharm total assets breakdown as of December 2025. United Pharm's total assets of ₩570.76 Billion consist of 51.7% current assets and 48.3% non-current assets. Explore United Pharm short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 7.8% |
| Accounts Receivable | ₩38.50 Billion | 7.4% |
| Inventory | ₩64.26 Billion | 12.4% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩10.55 Billion | 2.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how United Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: United Pharm's current assets represent 51.7% of total assets in 2025, an increase from 51.7% in 2011.
- Cash Position: Cash and equivalents constituted 7.8% of total assets in 2025, down from 10.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 12.4% of total assets.
United Pharm Competitors by Total Assets
Key competitors of United Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangxi Synergy Pharmaceutical Co Ltd
SHE:300636
|
China | CN¥3.31 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.95 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.73 Billion |
United Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.52 | 5.44 | 3.60 |
| Quick Ratio | 4.30 | 4.03 | 2.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩245.72 Billion | ₩204.57 Billion | ₩144.19 Billion |
United Pharm - Advanced Valuation Insights
This section examines the relationship between United Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.53 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 9.6% |
| Total Assets | ₩519.49 Billion |
| Market Capitalization | $166.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values United Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: United Pharm's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for United Pharm (2011–2025)
The table below shows the annual total assets of United Pharm from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩519.49 Billion ≈ $352.05 Million |
+9.61% |
| 2024-12-31 | ₩473.93 Billion ≈ $321.17 Million |
+1.08% |
| 2023-12-31 | ₩468.86 Billion ≈ $317.74 Million |
+12.20% |
| 2022-12-31 | ₩417.89 Billion ≈ $283.20 Million |
+9.96% |
| 2021-12-31 | ₩380.03 Billion ≈ $257.54 Million |
+7.53% |
| 2020-12-31 | ₩353.43 Billion ≈ $239.52 Million |
+6.70% |
| 2019-12-31 | ₩331.24 Billion ≈ $224.48 Million |
+9.70% |
| 2018-12-31 | ₩301.95 Billion ≈ $204.63 Million |
+13.60% |
| 2017-12-31 | ₩265.80 Billion ≈ $180.13 Million |
+13.48% |
| 2016-12-31 | ₩234.22 Billion ≈ $158.73 Million |
+7.89% |
| 2014-12-31 | ₩217.10 Billion ≈ $147.13 Million |
+12.17% |
| 2013-12-31 | ₩193.54 Billion ≈ $131.16 Million |
+3.18% |
| 2012-12-31 | ₩187.58 Billion ≈ $127.12 Million |
+10.28% |
| 2011-12-31 | ₩170.09 Billion ≈ $115.26 Million |
-- |
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more